The approval marks the first time gene therapy will be available to treat patients with aromatic I-amino acid decarboxylase ...

First-ever FDA approval for gene therapy directly administered to the brain - - Priority review voucher granted - - Broad label including children and adults - - ...

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD ...

Air pollution exposure is associated with an increased risk of developing Parkinson disease (PD) and dyskinesia, according to study results published in JAMA Network Open.

Patients should be monitored for procedure related adverse events with KEBILIDI administration. Dyskinesia: Dyskinesia was reported after administration of KEBILIDI. All events were reported within 3 ...

Supernus Pharmaceuticals is reaping the benefits of its ADHD drug Qelbree, with strong Q3 results and upwardly revised ...

A 28-year-old Middle Eastern man develops severe motor disturbances, including muscle rigidity, tremors, a parkinsonian gait, and involuntary, jerky limb movements, following the administration of a 3 ...

A new study published in the Asian Journal of Psychiatry showed that people of Indian heritage require lower effective ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday said data from Phase 3 KINECT-3 and KINECT-4 studies showed that treatment with Ingrezza brought holistic improvements over time in patients with ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new patient- and physician-reported ...